Navigating the path forward for evidence-based management of long COVID

Affiliations

¹ National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
² Foundation for the National Institutes of Health, North Bethesda, MD, USA.
³ National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. jeanne.marrazzo@nih.gov.

^# Contributed equally.

Joseph J Breen et al. Nat Immunol. 2025 Apr.

. 2025 Apr;26(4):536-539.

doi: 10.1038/s41590-025-02118-6.

¹ National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
² Foundation for the National Institutes of Health, North Bethesda, MD, USA.
³ National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. jeanne.marrazzo@nih.gov.

^# Contributed equally.

No abstract available

Conflict of interest statement

Competing interests: All authors declare they have no conflicts of interest.

1. Al-Aly, Z. et al. Nat. Med. 30, 2148–2164 (2024). - DOI - PubMed
1. Fang, Z., Ahrnsbrak, R. & Rekito, A. JAMA 332, 5–6 (2024). - DOI - PubMed
1. Goldowitz, I., Worku, T., Brown, L. & Fineberg, H. V. (eds). A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences page 3 (National Academies Press, 2024).
1. Montealegre Sanchez, G. A. et al. Pediatr. Res. https://doi.org/10.1038/s41390-024-03777-1 (2024). - DOI - PubMed
1. Gross, R. S. et al. JAMA 332, 1174–1188 (2024). - DOI - PubMed - PMC